PACLITAXEL BY 1-HOUR INFUSION - AN ACTIVE-DRUG IN METASTATIC NON-SMALL-CELL LUNG-CANCER

Purpose: Paclitaxel is an active single agent when administered as a 24-hour continuous infusion in the treatment of stage IV non-smell-cell lung cancer. We evaluated the efficacy and toxicity of paclitaxel administered by 1-hour infusion in the outpatient setting to patients with stage IV or relapsed non-small-cell lung cancer. Patients and Methods: Fifty-nine patients with stage IV or relapsed non-small-cell lung cancer were treated with 1-hour infusions of paclitaxel. The first 17 patients received a dose of 135 mg/m(2) and the remaining 42 patients received 200 mg/m(2). By random assignment, 31 patients received a single-day, 1-hour infusion of paclitaxel, and 28 patients received a 3-day, divided-dose schedule, with each dose administered by 1-hour infusion. Both regimens were repeated every 21 days. All patients received premedication with dexamethasone, diphenhydramine, and cimetidine. Cytokines were not routinely used. Results: Thirteen of 53 assessable patients (25%) had partial responses to treatment. An additional five patients had minor responses. The median survival duration of the entire group was 8 months and the actuarial 1-year survival rate was 33%. Patients who received 200 mg/m(2) of paclitaxel had a higher response rate than those who received 135 mg/m(2) (31% v 12%, respectively). Six of 16 patients (38%) previously treated with cisplatin-based regimens responded to 200 mg/m(2) of paclitaxel. No significant differences in activity were seen when the 1-day and 3-day paclitaxel schedules were compared. Paclitaxel was well tolerated at both doses and schedules, and no severe hypersensitivity reactions occurred. Only 18 of 154 courses (12%) given at 200 mg/m(2) resulted in grade 3 or 4 leukopenia. Conclusion: Paclitaxel administered by 1-hour infusion is an active and well-tolerated new agent in the treatment of metastatic non-small-cell lung cancer. These results suggest that a paclitaxel dose of 200 mg/m(2) is more effective than 135 mg/m(2) and can produce responses in patients previously treated with cisplatin-based regimens. Incorporation into combination regimens is indicated.